BRAF inhibitor arrest tumor growth by inhibiting the ERK pathway. This relieves ERK negative feedback on RAS, partially restoring RAS activity leading to RAS-induced BRAFV600Edimers. BRAF inhibitors bind one and transactivate the other BRAF, reducing BRAF inhibitor therapy. Here, BRAF is linked to neoplasm.